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1. Introduction 
Prostate cancer is the most common malignancy in men in the Netherlands. The majority of 
patients with advanced prostate cancer develop skeletal metastases, with bone pain as a 
frequent symptom. This poses a significant medical problem. Amongst other treatments, 
bone seeking radiopharmaceuticals are used to palliate painful metastatic bone disease. 
Efficacy has been sufficiently proven, as well as safety and feasibility. Practical issues as well 
as new developments and future prospects will be discussed. 
This chapter will discuss the treatment of metastatic bone pain in hormone-refractory 
prostate cancer patients with bone seeking radiopharmaceuticals. Two main issues will be 
discussed: 
1. Bone seeking radiopharmaceuticals in clinical practice. Issues regarding radiation safety 
and a protocol for routine use of bone seeking radiopharmaceuticals will be discussed 
in order to improve routine clinical care. 
2. Enhancement of efficacy of bone seeking radiopharmaceuticals. 
But first a short introduction will be given on clinical relevance and bone seeking 
radiopharmaceuticals in general. 
2. Prostate cancer and skeletal metastases 
The incidence of malignancy in the Netherlands was 74.500 patients in 2005. This will 
increase to approximately 95.000 new cases in 2015. Because malignancy related death is 
decreasing and it is likely to decrease further the prevalence of cancer patients will increase 
to an estimated 692.000 patients in 2015, compared to 366.000 in 2000 (an estimated doubling 
time of 15 years) (Coebergh, van de Poll-Franse, and Alers 2004; Visser and van Noord 
2005). One of the major causes of cancer related death in men is prostate cancer. These 
patients will be the focus of this chapter. 
The incidence of prostate cancer is high worldwide. It is the most common malignancy in 
men in the Netherlands. Approximately 9000 men are being diagnosed with prostate cancer 
each year (Figure 1). The rising incidence may be attributed to the incremental use of 
screening methods using prostate specific antigen (PSA) to detect prostate cancer. This 
hypothesis is supported by the growing number of patients being diagnosed with early 
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stages of prostate cancer. The incidence also increases with age. Consequently, with a 
growing number of old men in our society the incidence of prostate cancer will further 
increase. Fortunately mortality from prostate cancer is decreasing due to better diagnostic 
methods and treatments (Dijkman and Debruyne 1996). 
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Fig. 1. Prostate cancer incidence between 1989 – 2005 derived from data on www.ikcnet.nl 
A hallmark of metastatic prostate cancer is the development of osteoblastic bone 
metastases. Almost all patients with advanced prostate cancer eventually develop osseous 
metastases. In a majority of patients with prostate cancer, bone is the only site of clinical 
metastases. Many of the established prognostic factors for advanced prostate cancer (eg, 
performance status, alkaline phosphatase level, and haemoglobin level) reflect the clinical 
consequences of bone metastases. Hence, patients who develop widespread, progressive, 
or early bone metastases tend to suffer more from their symptoms and fare worse. 
Conversely, patients who develop limited, stable, or delayed bone metastases tend to 
experience less morbidity and have a less dismal clinical outcome. Conceivably, targeting 
the relevant bone metastases–associated factors may improve therapeutic results (Tu and 
Lin 2008). These factors consist of the main cells involved in bone metastasis (cancer cells, 
osteoblasts, osteoclasts, endothelial cells and stromal cells) and the numerous 
communicating substances (eg, interleukins, VEGF, RANKL, TNF-alfa, endothelins). They 
form a complex interaction and a microenvironment in which cancer cells may flourish 
(Tu and Lin 2008). 
Frequently these skeletal metastases cause pain. Less common complications include 
myelum compression and pathological fractures (Dijkman and Debruyne 1996). Besides 
hormonal treatment most other treatment modalities in advanced prostate cancer patients 
are intended to palliate bone pain. Metastatic bone pain is a nociceptive somatic pain, 
initiated and maintained through local tissue injury. It is well recognized that chronic 
pain (including cancer pain) is a multidimensional phenomenon consisting of five 
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dimensions (pathophysiological, sensory, emotional, cognitive, and behavioural). These 
five dimensions together form a complex pattern of relations (Quirijnen et al. 1996).  Stress 
is a well known stimulus for nociceptive pain. The impression that pain may be 
uncontrollable produces stress for patients, which may lead to increased suffering and 
despair, and decreases the patient's performance (Chapman and Gavrin 1999). An 
effective pain management strategy requires breaking off this cycle using all available 
means. An effective pain control strategy, however, requires patients to take large 
quantities of opioids, often as much as 60 – 200 mg/day. This large dose may cause 
considerable side effects, including nausea, vomiting, constipation, and central sedation, 
all of which combine to a decrease in quality of life. Patients will have to take large doses 
of anti-emetics and laxatives to counteract nausea and constipation, respectively. Central 
sedation increases drowsiness, resulting in frequent falls, bone fractures, and driving 
accidents (Etches 1999). Supplemental therapy with local radiation, wide-field radiation, 
bisphosphonates, or bone seeking radiopharmaceuticals can significantly reduce the dose 
of opioids for most patients or may even completely eliminate the need for the 
medications in a few patients (Krishnamurthy and Krishnamurthy 2000). 
Metastatic disease in prostate cancer may be treated first with hormonal therapy such as 
bilateral orchidectomy or medical first line hormone treatment (luteinizing hormone-releasing 
hormone agonist therapy). This androgen-deprivation therapy may be extended to maximal 
androgen blockade by adding anti-androgens (bicalutamide, flutamide, nilutamide). High risk 
prostate cancer patients may benefit from such a regimen even in the early stages of the 
disease (Klotz 2008). It is also recognized that discontinuation of an anti-androgen once 
hormone-refractory biochemical progression occurs is associated with a biochemical response 
in many patients. Anti-androgens may become agonistic due to a combination of androgen 
receptor over-expression and mutation (Kelly and Scher 1993; Small and Srinivas 1995). After a 
median of two years the prostate cancer cells generally become insensitive for hormonal 
treatment. In the case of hormone-refractory disease the patient may be treated by 
chemotherapy, local radiotherapy, systemic radiopharmaceuticals, bisphosphonates and 
analgesics, depending on the clinical status (Auclerc et al. 2000). 
The clinical benefit of chemotherapy in hormone-refractory prostate cancer patients is limited. 
Some drugs showed potential as first-line treatment in hormone-refractory prostate 
carcinoma but were not sufficiently tested in clinical trials (Berthold, Sternberg, and 
Tannock 2005). Patients however may benefit from docetaxel chemotherapy in combination 
with prednisone. In a landmark study treatment with 75 mg/m2 docetaxel i.v. every three 
weeks with 5 mg prednisone twice daily p.o. was compared with mitoxantrone 12 mg/m2 
every three weeks (Tannock et al. 2004). The median survival increased from 16.3 months in 
the mitoxantrone-group to 19.2 months in the docetaxel-group (Berthold et al. 2008). The 
group receiving docetaxel three weekly had a hazard ratio for death of 0.79 (95 percent 
confidence interval, 0.67 to 0.93; p=0.004) compared to the mitoxantrone-group (Berthold et 
al. 2008). Pain and quality of life improved significantly better in the docetaxel group and 
more patients (45% versus 32%; p<0.001) showed a 50% reduction of serum PSA levels 
(Tannock et al. 2004). However, docetaxel nor any other treatment will be curative in an 
advanced stage of prostate cancer. 
Patients with hormone-refractory prostate cancer who have progressive disease after first-
line chemotherapy may still benefit from several treatment options. At this stage of disease, 
patients can expect only a short duration of survival, and most patients become 
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symptomatic. Most patients will cease docetaxel treatment because of progressive disease or 
unacceptable adverse events. To control symptoms after the cessation of chemotherapy 
should rely on optimizing medical therapy for palliation. This may be combined with 
radiotherapy applied to dominant painful bone lesions. External beam radiotherapy for 
painful skeletal metastases leads to a decrease of pain in 60 – 65% of the patients. In 33% of 
the patients a total remission of pain symptoms was observed (McQuay et al. 2008). Patients 
may be treated in one fraction (8 Gray). No difference has been found between such a single-
dose regimen and multiple fractions (Hartsell et al. 2005; Kaasa et al. 2006; Roos et al. 2005). 
Furthermore, when needed, patients may be treated a second time with a reported response 
rate between 66% and 84% (Mithal, Needham, and Hoskin 1994; Van der Linden et al. 2004). 
Besides chemotherapy further hormonal manipulation with prednisone or dexamethasone 
may have some benefit as well. Glucocorticoids may lead to PSA response and/or relief of 
symptoms in patients with late-stage prostate cancer (Tannock et al. 1989). Some investigators 
have suggested that the superior results of regimens with taxanes may be due in part to the 
dexamethasone that is administered to avoid toxic reactions to these drugs. However, most 
patients have already received substantial treatment with glucocorticoids concurrent with 
first-line chemotherapy, so their potential benefit in later stages is probably minimal. 
Other treatment options in the advanced stage of prostatic cancer include ketoconazole and 
estrogens. Inhibition of steroid synthesis by ketoconazole may increase the probability of an 
anti-androgen withdrawal response, although this did not translate into improved survival 
(Small et al. 2004). Estrogens may improve symptoms but caution must be used because of 
their ability to stimulate thrombosis and cardiovascular events. Estrogens were found to be 
equivalent to estramustine (which contains estrogen), probably as its activity is largely due to 
the estrogen component (Small et al. 2000). Transdermal administration of oestrogens through 
a patch avoids the entero-hepatic circulation and therefore it should not be associated with the 
same level of cardiovascular toxicity. Early data confirm the safety and efficacy of oestrogen 
patches as hormonal treatment in prostate cancer patients (Langley et al. 2008). 
Currently new non chemotherapeutic options are studied such as endotheline antagonists 
(James et al. 2008) and abiraterone acetate, a potent, selective, small-molecule inhibitor of 
cytochrome P (CYP) 17, a key enzyme in androgen synthesis (Attard et al. 2008). Many other 
agents are being developed (Tu and Lin 2008). 
3. Bone seeking radiopharmaceuticals 
Bone seeking radiopharmaceuticals have proven to be useful for treatment of more 
generalized bone pain. All patients will finally progress to end stage disease with multiple 
skeletal metastases. These patients may receive bone seeking radiopharmaceuticals for 
generalized painful disease (Berthold, Sternberg, and Tannock 2005). The association of 
integrated cancer centres in the Netherlands (VIKC) developed an evidence based guideline 
on the diagnosis and treatment of pain in cancer patients. Radionuclide treatment of cancer 
patients with metastatic bone pain (so called bone seeking radiopharmaceuticals) was 
evaluated using all available literature (VIKC 2008). The conclusions are stated together 
with their level of evidence in Table 1. 
Most of the patients who have participated in the mentioned trials were heavily pre-treated 
patients with previous radiotherapy, chemotherapy and/or hormone therapy. It was 
recommended that radionuclide treatment with bone seeking radiopharmaceuticals is 
indicated in patients with multifocal pain originating from osteoblastic skeletal metastases. 
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Repeated treatments are indicated after an initial response to treatment. The committee had 
the opinion that combined multimodality treatment should be performed in a trial setting. 
Further research in that field is warranted (VIKC 2008). 
Radionuclide therapy with bone seeking radiopharmaceutical agents has been long used. It 
evolved from agents like 32P-phosphate to newer agents like 188Re-HEDP or 223Ra (Table 2). 
Bone seeking radiopharmaceuticals consist of a radionuclide for the therapeutic effect and a 
carrier to reach the target site at the bone matrix level. Sometimes the carrier and the 
radionuclide are one and the same. This is the case for 32P-phosphate, 223Ra and 89Sr. These 
radiopharmaceuticals behave as physiologic phosphate (32P-phosphate) or Ca2+-analogues 
(223Ra and 89Sr). They do not need a non-radioactive substance as a carrier to reach the 
target. Carriers like hydroxyethylenediphosphonic acid (HEDP in 186Re-HEDP) and 
ethylenediaminetetramethylenephosphonic acid (EDTMP in 153Sm-EDTMP) are being used 
in other bone seeking radiopharmaceuticals. They behave as bisphosphonates. These 
differences influence the biodistribution and pharmacokinetics of the pharmaceutical. Other 
differences between these agents include the radiation type, the radiation energy and the 
radionuclide half-life.  
One thing that never changed during the last decades and stimulated the search for new 
agents was the conflict between efficacy and toxicity. The latter consisting of bone marrow 
suppression in particular. This has even led to a change of indication for the use of 32P-
phosphate. It is not used anymore for the palliation of metastatic bone pain but instead for 
the treatment of myeloproliferative diseases, making use of its bone marrow suppressive 
potential (Berlin 2000; Cheung and Driedger 1980). Fortunately newer agents have proved to 
be feasible and relatively safe for the palliative treatment of osseous metastases with 
acceptable and reversible bone marrow toxicity. 
 
Conclusion Evidence a Study type b 
It has been proven that treatment with 
bone seeking radiopharmaceuticals 
yields a better pain response than 
treatment with placebo in patients with 
painful osseous metastases from diverse 
cancers including prostate, breast and 
lung cancer. 
Level 1 
A1 (Bauman et al. 2005; Finlay, 
Mason, and Shelley 2005; 
McQuay et al. 2008; Roque i 
Figuls et al. 2008) 
A2 (Han et al. 2002; Lewington et 
al. 1991; Maxon, III et al. 1991; 
Sartor et al. 2004; Serafini et al. 
1998) 
   
It has been proven that no difference 
exists with regard to local pain response 
between treatment with 89Sr-Chloride or 
external beam radiotherapy in patients 
with painful osseous metastases from a 
prostate carcinoma. 
Level 1 
A2 (Oosterhof et al. 2003; Quilty 
et al. 1994) 
   
It is likely that no difference exists with 
regard to pain response between 
treatment with 89Sr-Chloride and 186Re-
HEDP in patients with painful osseous 
metastases. 
Level 2 
A2 (Sciuto et al. 2001) 
B (Piffanelli et al. 2001) 
www.intechopen.com
 
Prostate Cancer – Diagnostic and Therapeutic Advances 
 
220 
Conclusion Evidence a Study type b 
   
It is likely that the onset of the pain 
response of 186Re-HEDP is faster than 
the onset of the pain response of 89Sr-
Chloride in patients with painful 
osseous metastases from a breast 
carcinoma. 
Level 2 A2 (Sciuto et al. 2001) 
   
It is likely that combined treatment with 
89Sr-Chloride and chemotherapy 
(platinum based) yields a better pain 
response than treatment without 
chemotherapy in patients with painful 
osseous metastases from a prostate 
carcinoma. 
Level 2 
A2 (Sciuto et al. 2002) 
C (Sciuto et al. 1996) 
   
It has been suggested that adding 89Sr-
Chloride to chemotherapy may lead to 
improved survival and a longer 
duration of the pain response 
compared to treatment with 
chemotherapy alone. 
Level 3 B (Tu et al. 2001) 
   
It has been suggested that no difference 
exists with regard to the pain response 
after treatment with chemotherapy or 
89Sr-Chloride in patients with painful 
osseous metastases from a prostate 
carcinoma. 
Level 3 B (Nilsson et al. 2005) 
   
No conclusions can be drawn on the 
value of adding 89Sr-Chloride to 
external beam radiotherapy in patients 
with painful osseous metastases from a 
prostate carcinoma because of 
conflicting results. 
 
A2 (Porter et al. 1993; Smeland 
et al. 2003) 
a Level of evidence: 1) A1 or at least two independent and consistent A2 studies; 2) One A2 study or at 
least two independent and consistent B studies; 3) One B or C study; 4) Professional opinion. 
b Quality and methodology of studies: A1) Systemic review of at least two independent A2 trials; A2) 
Double-blind randomized trial of sufficient size and quality (comparison with a reference test (‘gold 
standard’), defined endpoints, independent evaluation of both tests, no confounding); B) Comparative 
trial not meeting A2 criteria;  
c Non-comparative trial; D) Professional opinion. 
 
Table 1. Evidence based conclusions on treatment with bone seeking radiopharmaceuticals 
(VIKC 2008). 
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Radiopharmaceutical Half-life (days) 
┚-emission MeV 
max (mean) 
┛-emission 
keV (%) 
188Re-HEDP 0.7 2.12 (0.76) 155 (15%) 
153Sm-EDTMP 1.93 0.81 (0.23) 103 (29%) 
186Re-HEDP 3.7 1.07 (0.35) 137 (9%) 
177Lu-EDTMP 6.7 0.497 (0.15) 208 (11%) 
223Ra 11.4 Emits alfa-particles of circa 5.7 MeV 
117mSn-DTPA 13.6 Emits conversion electrons 127 – 152 keV 
32P-Phosphate 14.3 1.71 (0.70) None 
89Sr 50.5 1.46 (0.58) 910 (0.01%) 
Table 2. Bone seeking radiopharmaceuticals categorized by half-life. 
All patients with proven osteoblastic (or mixed type) skeletal metastases that accumulate 
99mTc-HDP on skeletal scintigraphy may be candidates for treatment with bone seeking 
radiopharmaceuticals. They may be cancer patients with advanced disease originating from 
prostate cancer, breast cancer, lung cancer, medullary thyroid carcinoma, or other tumors 
(i.e. bronchial carcinoid tumors, medulloblastoma). In routine clinical practice the vast 
majority of patients are prostate cancer patients. In these patients the incidence of skeletal 
metastases is very high. They cause high morbidity and mortality (DePuy et al. 2007; Saarto 
et al. 2002). Metastases originating from prostate cancer are pure osteoblastic with relatively 
high radionuclide uptake, resulting in high tumor to non-tumor ratio’s. And last but not 
least other treatment options are limited in advanced stages of this disease. 
In the growing field of radionuclide therapy many new radiopharmaceuticals are being 
developed. At the moment 89SrCl2 (Metastron®) and 153Sm-EDTMP (Quadramet®) are both 
FDA approved. Together with 186Re-HEDP (registered in some countries, not in the 
Netherlands) these bone seeking radiopharmaceuticals are mostly used today. 
4. Bone seeking radiopharmaceuticals in clinical practice 
4.1 Radiation safety considerations 
Patients treated with any kind of radionuclide treatment must be regarded as a potential 
risk for public health because of a potential radiation hazard. Good understanding of the 
radionuclide used, its physical characteristics, its biodistribution and its pharmacokinetics, 
will allow us to draw proper guidelines for this kind of treatment. Does the patient need to 
be confined after treatment? Are we able to identify the radiation hazard from a qualitative 
and quantitative perspective? What does that mean for an individual patient in relation to 
its environment? 
Patients treated with 89SrCl2, 186Re-HEDP or 153Sm-EDTMP are a source of radiation, 
including beta-radiation that has proven to be measurable outside the patient. Beta-
particles in superficial tissue (such as in bones, blood vessels) cross the skin and 
contribute to the ambient equivalent dose. This aspect must be considered when using 
beta-emitting radiopharmaceuticals in general. The calculated effective doses for 
bystanders are well below the recommended values and do not lead to unacceptable 
additional radiation burden to health care workers and patients’ families. The mean total 
effective doses absorbed by bystanders at 30 cm distance from a patient are approximately 
0.02 mSv for 89SrCl2, 0.3 mSv for 186Re-HEDP, and 1.6 mSv for 153Sm-EDTMP (Lam et 
al. 2009b). These observations however should be placed in some perspective. First the 
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individual variation in effective dose to bystanders and second the potential risk of 
internal contamination of bystanders. 
The total effective dose, as given above, is estimated for bystanders who reside at exactly 30 
cm from the patient for an indefinite time. Because this is never the case, these estimations 
must be corrected for variations in time and distance between bystanders and patients. In a 
Dutch Ministry of Housing, Spatial Planning and Environment publication accurate 
calculations were made to cover the various persons who may have contact with patients 
(VRO92; VROM 2005). These calculations are based on residence times T (in fractions of 
days) with the patient and distances R (in meters) from the patient. The actual effective 
doses for bystanders will depend on residence times and distances in relation to the patient. 
Estimations were made for residence times and distances during a 24-hour period. This was 
done in the case of an elderly patient in relation to his or her partner and in the case of a 
patient in relation to his or her child (Tables 3 and 4). 
 
 Without instruction With instruction 
 Residence 
time 
(hrs/24hrs) 
Distance 
(m) 
Correction 
factor a 
Residence 
time 
(hrs/24hrs) 
Distance 
(m) 
Correction 
factor a 
outdoors 
activities 
3/24 - 0 3/24 - 0 
watching 
TV 
5/24 0.5 0.075 5/24 2 0.0047 
dinner 2/24 1 0.0075 2/24 1 0.0075 
sleeping 8/24 0.7 0.061 8/24 2 0.0075 
other 6/24 3 0.0025 6/24 3 0.0025 
total   0.15   0.02 
 Mean effective dose (mSv) Mean effective dose (mSv) 
153Sm-
EDTMP 
0.24 0.03 
186Re-
HEDP 
0.05 < 0.01 
89Sr-
Chloride 
< 0.01 < 0.01 
a Correction factor applicable for measurements at 30 cm from the patient using the inverse-square law 
Table 3. Effective dose (external radiation) of an elderly partner with and without 
instructions. 
Assuming that the estimated distances and times are a reflection of reality, corrections were 
made for these circumstances. Estimations of the effective doses for these persons (partner 
and child) are given for the three most used radiopharmaceuticals. In the case of a patient 
and his or her partner, without instructions a correction factor of 0.15 (15%) was applied. 
This is explained by the fact that bystanders do not stay within 30 cm of patients 24 hours a 
day. Because of work and other activities a correction factor should be applied. As an 
example a correction factor of 0.15 may be applied. The effective dose may be further 
reduced by instructing the patients and their families to keep distance as much as 
reasonably possible (e.g. watching TV and sleeping apart). With proper instructions to 
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family, residence times may be reduced and distances increased, lowering the correction 
factor to as low as 0.02 (2%), an almost eight-fold decrease in radiation burden to bystanders 
(Table 3). In the case of a patient and his or her child an estimated correction factor of about 
0.43 (43%) should be applied without instructions and 0.11 (11%) with instructions. In all 
instances effective doses will be < 1 mSv and with proper instructions they will be < 0.1 mSv 
or even < 0.01 mSv (Tables 3 and 4). It may be concluded that patients treated with bone 
seeking radiopharmaceuticals do not pose any threat to others. 
 
 Without instruction With instruction 
 Residence 
time 
(hrs/24hrs) 
Distance 
(m) 
Correction 
factor a 
Residence 
time 
(hrs/24hrs) 
Distance 
(m) 
Correction 
factor a 
playing 8/24 4 0.0019 8/24 4 0.0019 
close 
contact 
1/24 0.1 0.375 0.25/24 0.1 0.094 
dinner 2/24 0.5 0.03 2/24 2 0.0019 
sleeping 10/24 - - 10/24 - - 
other 3/24 2 0.0094 3/24 2 0.0094 
total   0.43   0.11 
 Effective dose (mSv) Effective dose (mSv) 
153Sm-
EDTMP 
0.69 0.18 
186Re-
HEDP 
0.13 0.03 
89Sr-
Chloride 
< 0.01 < 0.01 
a Correction factor applicable for measurements at 30 cm from the patient using the inverse-
square law 
Table 4. Effective dose (external radiation) of a young child with and without instructions. 
However, an exception has to be made considering urinary excretion of activity and the 
possible internal contamination of bystanders. Besides radiation exposure to non-patients 
from direct emission by the patient, another potential radiation hazard is formed by 
excreted radioactivity. The calculated mean total urinary excretion percentage of 89Sr during 
the first 3 days after administration was 16% (Lam et al. 2009b). Using a hypothetical 
contamination scenario, that is used in radiation protection evaluation (VROM 2005), that 
0.01% of the excreted amount of radioactivity will cause internal contamination to non-
patients closely related to the patient, an internal dosage of 0.0024 MBq for 89SrCl2 therapy 
(administered dose of 150 MBq) was calculated. For 186Re-HEDP therapy (administered dose 
of 1295 MBq), the corresponding amount of radioactivity will be 0.064 MBq (49% of the 
injected dose is excreted (de Klerk et al. 1992)). After treatment with 37 MBq/kg 153Sm-
EDTMP 53.1% ± 15.1% of the administered dose was excreted in urine during the first 48 
hours (Lam et al. 2007). Potential contamination with 0.01% of the excreted radioactivity will 
lead to an internal dosage of 0.15 MBq 153Sm-EDTMP. The dose conversion coefficient for 
ingestion of 89Sr is (eing) = 2.6 x 10-9 Sv/Bq, of 186Re (eing) = 1.5 10-9 Sv/Bq, and of 153Sm (eing) 
= 7.4 10-10 Sv/Bq. The present data show that the effective radiation absorbed dose, caused 
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by a potential internal contamination (0.01% of the administered dose), is 6.2 microSv for 
89Sr, 96 microSv for 186Re and 111 microSv for 153Sm. These numbers are in the same order of 
magnitude as the numbers given for external exposure (Table 3 and 4). 
The total effective dose for non-patients may be caused by both external radiation exposure 
and internal contamination. In contrast to the mean effective dose caused by external 
radiation, the effective dose after ingestion of 0.01% of the administered dose is hypothetical 
and may be much higher or much lower. In the case of 131I it proved to be less. The uptake of 
131I in the thyroid of family members was measured (Buchan and Brindle 1970). A maximum 
uptake of 3.8 Bq per MBq administered was found. So on one hand it must be considered 
that 0.01% is a hypothetical figure, while the external radiation exposure is a fact. On the 
other hand, internal contamination poses a real threat to non-patients. Patients that were 
treated with bone-seeking radiopharmaceuticals are often severely disabled (in contrast to 
131I patients). Especially in the case of prostate cancer patients, they often have dysurea. 
Personal hygiene is not as obvious as it is to others. It is therefore advisable to give the 
patients simple, easy-to-follow instructions, in order to reduce the risk for non-patients. 
Using a separate toilet, sitting while urinating and washing hands afterwards, are highly 
recommended. In the case of incontinence, patients must be catheterized for a certain time 
depending on urinary excretion of the administered activity. Due to fast renal excretion this 
may be 12 hours after injection of 186Re-HEDP and 153Sm-EDTMP. 89SrCl2 is being 
administered in relatively low doses and therefore has a relatively low risk for high effective 
dose due to ingestion of this radiopharmaceutical (6.2 microSv for 89Sr). These patients do 
not have to be catheterized. The risk for significant internal contamination of non-patients is 
much lower and acceptable for this radiopharmaceutical. 
In general it is advised to hospitalize patients treated with 186Re-HEDP and 153Sm-EDTMP 
for at least 8 hours. This is mostly based on urinary excretion and the risk for internal 
contamination, because the radiation exposure to non-patients is < 20 microSv/hour (1 
meter from the patients) directly or within a few hours after administration in all cases. In 
the case of incontinence it is advised to treat patients with either 186Re-HEDP or 153Sm-
EDTMP with a urinary catheter for 12 hours after administration. Patients treated with 
89SrCl2 may return home directly. 
After discharge it is advisable to keep distance where possible (Table 3 and 4), following the 
ALARA (‘as low as reasonably achievable’) principles. This means, for example, that older 
patients (> 60 years) may still sleep close to their older partner, while being more stringent 
towards younger relatives to avoid any unnecessary radiation dose. The ICRP has proposed 
an effective dose limit of 1 mSv per year for individuals. In special circumstances a higher 
value may be allowed in a single year provided that the average over 5 years does not 
exceed 1 mSv per year. In clinical practice, the use of bone-seeking radiopharmaceuticals 
will give rise to a degree of radiation exposure to all those in contact with patients, albeit in 
very low doses. The present results further confirm the safety of treatment with bone-
seeking radiopharmaceuticals. 
4.2 Treatment recommendations 
89SrCl2 (Metastron®) and 153Sm-EDTMP (Quadramet®) are both FDA approved and registered 
in the Netherlands. Together with 186Re-HEDP (registered in some countries, not in the 
Netherlands) these bone seeking radiopharmaceuticals are mostly used. Most of the 
randomized double-blind placebo controlled trials have been performed using 89SrCl2 or 153Sm-
www.intechopen.com
 
Bone Seeking Radiopharmaceuticals for Metastatic Bone Pain 
 
225 
EDTMP. An evidence based approach would be a choice between these radiopharmaceuticals. 
One of the differences between these two is the magnitude and rate of renal excretion. Both 
may be used without confining a patient to the hospital but from a radiation safety perspective 
it is advised to keep the patient in a controlled setting for at least 8 hours after injection in the 
case of 153Sm-EDTMP. This could influence the choice on practical grounds in favour of 89SrCl2. 
Not all nuclear medicine departments have such facilities. 
Other differences include the longer half-life and higher energy (with higher range in tissue) 
of 89SrCl2 compared to 153Sm-EDTMP. 153Sm-EDTMP and 186Re-HEDP are highly comparable 
with regard to energy and half-life. Most comparative randomized studies have been 
performed using 89SrCl2 and 186Re-HEDP. It was found that no difference exist with regard 
to pain response between treatment with 89Sr-Chloride and 186Re-HEDP in patients with 
painful osseous metastases (Piffanelli et al. 2001; Sciuto et al. 2001). And that the onset of the 
pain response of 186Re-HEDP is faster than the onset of the pain response of 89Sr-Chloride in 
patients with painful osseous metastases from a breast carcinoma (Sciuto et al. 2001). So one 
might argue that when a faster pain response is indicated one should use 186Re-HEDP or 
153Sm-EDTMP. Other differences are the longer duration of response of 89Sr-Chloride on one 
hand, and the prolonged bone marrow toxicity of 89Sr-Chloride on the other hand. These 
differences were not investigated in direct comparative studies but should be considered 
nevertheless. In summary: in favour of 89Sr-Chloride are: 
 No confinement necessary 
 Longer duration of response (suitable in relatively good clinical condition in which a 
prompt response is not warranted) 
In favour of 186Re-HEDP or 153Sm-EDTMP are: 
 Fast response (suitable in bad clinical condition in which immediate response is 
wanted) 
 Favourable toxicity profile (suitable in heavily pre-treated patients, in wide spread 
metastatic disease and possibly in combination with other myelotoxic treatments) 
In most cases today a fast response is needed. Besides that most patients, including prostate 
cancer patients, are heavily pre-treated. They have end stage disease with minimal bone 
marrow reserve. And last but not least short-living bone seeking radiopharmaceuticals like 
186Re-HEDP, 153Sm-EDTMP and others may prove to be more suitable in combination with 
other treatment modalities, not just because of their toxicity profile but also because of their 
high dose rate, offering an effective treatment with fast recovery. 
5. Enhancement of efficacy 
A major concern in the treatment of prostate cancer patients in the more advanced stage of 
the disease is the delicate balance between efficacy and toxicity. Treatment of metastatic 
bone pain with analgesics or localized external beam radiotherapy is relatively safe and 
easy. Treatment with bone seeking radiopharmaceuticals may be more appropriate in 
selected cases but efficacy is sometimes disappointing and bone marrow toxicity may be 
high in individual patients. Enhancement of overall efficacy without increasing toxicity 
could push the clinical decision algorithm in a positive direction with regard to the use of 
bone seeking radiopharmaceuticals. 
One way of improving overall efficacy is combined treatment. Combined treatment 
regimens may deliver the beneficial effect of two different treatment modalities. These 
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combinations may not only be additive but possibly synergistic to each other, leading to 
enhancement of overall efficacy with acceptable toxicity. 
5.1 Multimodality treatment 
The propensity of prostate cancer to metastasize to bone and the prognostic significance of 
bone metastases suggest that effective treatment of bone metastases may provide clinical 
benefits (DePuy et al. 2007; Sabbatini et al. 1999). With regard to the ‘seed’ and ‘soil’ theory 
on bone metastases the seed may comprise the so-called cancer stem cells. Whereas the soil 
may comprise a unique microenvironment, that facilitate the growth and survival of cancer 
stem cells. Targeting the microenvironment may offer another way to improve treatment of 
prostate cancer bone metastases. The microenvironment consists of osteoclasts, osteoblasts, 
endothelium and stroma. In the presence of cancer stem cells they interact leading to a 
disruption in normal coupling between osteoclasts and osteoblasts. An improved 
understanding of this process will influence how we select agents to target bone metastases 
and how we design strategies to treat prostate cancer bone metastases. Treatments may be 
directed to the cancer stem cells, the osteoblasts, the osteoclasts, the endothelium or the 
stroma (Tu and Lin 2008). 
Osteoblasts may be targeted by several pharmaceuticals including bone seeking 
radiopharmaceuticals. Other osteoblast directed treatments include endothelin-1-
antagonists (atrasentan) (Carducci et al. 2003), vitamin D analogs (1,25-hydroxyvitamin D3) 
(Beer et al. 2007), monoclonal IGF-1R (insulin-like growth factor-1-receptor) antibodies 
(Boyle et al. 2001) and CXRC4 (G-protein-coupled receptor) inhibitors (MSX-122), which 
inhibit the homing behaviour of cancer stem cells. Osteoclast activity may be inhibited by 
bisphosphonates (zolendronate) (Saad et al. 2002), RANK ligand inhibitors (denosumab) 
(Lewiecki 2006), tyrosine kinase inhibitors (dasatinib) or IL-6 antagonists (CNTO328) (Nam 
et al. 2005). And the endothelium and/or stroma may be targeted by anti-angiogenesis 
therapies. These include the vascular endothelial growth factor (VEGF) receptor antagonists 
bevacizumab, thalidomide and lenalidomide (Dahut et al. 2004). They reduce VEGF levels 
and basic fibroblast growth factor, inhibit growth and survival of tumor cells by modulation 
of adhesion molecules and mediate various cytokines.  Also targeted to the endothelium are 
platelet-derived growth factor receptor (PDGFR) tyrosine kinase inhibitors (imatinib, 
sunitinib and tandutinib) (Ko et al. 2001). They may also have anti-angiogenetic potential. 
Most of these agents are under investigation. Many clinical studies in prostate cancer 
patients are ongoing (Tu and Lin 2008). 
Combining different treatment modalities may be interesting because of additive effects 
or synergy effects. In the case of bisphosphonates and bone seeking radiopharmaceuticals 
the combined use has always been contra-indicated because of presumed interaction at 
the bone matrix level. It was shown that the combined use of 153Sm-EDTMP and 
bisphosphonates in patients with hormone-refractory prostate carcinoma is feasible. The 
combined treatment regimen is safe and may prove to be an effective long-term treatment 
regimen (Lam et al. 2007). 
Another combined treatment regimen would be a combination of bone seeking 
radiopharmaceuticals and chemotherapy. It is likely that combined treatment with 89Sr-
Chloride and chemotherapy (platinum based) yields a better pain response than treatment 
without chemotherapy in patients with painful osseous metastases from a prostate 
carcinoma (Sciuto et al. 2002), (Sciuto et al. 1996). And it has been suggested that adding 
www.intechopen.com
 
Bone Seeking Radiopharmaceuticals for Metastatic Bone Pain 
 
227 
89Sr-Chloride to chemotherapy may lead to improved survival and a longer duration of the 
pain response compared to treatment with chemotherapy alone (Tu et al. 2001). Studies are 
yet limited but they are encouraging. Most of them have been performed using 89Sr-
Chloride and some using 153Sm-EDTMP (Ricci et al. 2007). Patients may possibly have an 
improved pain response and longer survival. In prostate cancer patients a most interesting 
choice would be combining docetaxel and a bone seeking radiopharmaceutical. These 
studies, using 153Sm-EDTMP or 186Re-HEDP, are underway. Our group investigated the 
combination of 188Re-HEDP and capecitabine (Xeloda®) (Lam et al. 2009a). This treatment 
regimen proved to be feasible and safe. Phase II efficacy testing using the maximum 
tolerable dose of 2500 mg/m2/day capecitabine is underway. Capecitabine is primarily used 
as a radiation sensitizer. It offers a convenient therapy with acceptable toxicity, ease of use 
as oral tablets and low costs. The same is true for 188Re-HEDP. It is homemade on demand 
and has favourable physical characteristics with a short half-life (16.9 hours) and high beta-
energy (E┚ max 2.12 MeV; E┚ mean 0.76 MeV). In theory, this high dose rate could lead to 
improved efficacy with rapid recovery. This is ideal for combined treatment regimens and 
for repeated treatment, which has already shown to be favourable with regard to pain 
response and survival (Palmedo et al. 2003). 
Several other combinations using bone seeking radiopharmaceuticals are under 
investigation. Currently, a randomized phase III study (MDA-3410/CTSU in M.D. 
Anderson Cancer Center, Houston, Texas) combining weekly doxorubicin (20 mg/m2) with 
89Sr-Chloride after response to induction chemotherapy is underway, as well as another 
phase I trial combining docetaxel/prednisone and 153Sm-EDTMP, also at M.D. Anderson 
(Tu and Lin 2008). It remains to be established whether targeting both the tumor 
(chemotherapy) and bone compartments will improve therapeutic efficacy. This concept is 
also being tested in multiple other trials, mostly combining docetaxel/prednisone with bone 
environment directed treatments, like the agents described above (Tu and Lin 2008). The 
described studies add to this search for optimized treatment regimens in hormone-
refractory prostate cancer patients.  
5.2 Predictions of efficacy and toxicity 
Most patients with advanced prostate cancer have disease limited to the bone, which is 
notoriously difficult to assess for response, with a small subset having soft tissue lesions. To 
limit response evaluation to only patients with bidimensionally measurable disease would 
eliminate 70% to 80% of patients who would otherwise be evaluable (Figg et al. 1996). With 
regard to prostate cancer patients efficacy of treatment has been monitored by PSA in a 
majority of studies. However it is doubtful whether PSA changes correlate with clinical 
benefit (Bubley et al. 1999). A 50% decrease in PSA level seems a reasonable predictor of a 
favourable outcome, but this was certainly not the case in all studies (Bauer et al. 1999; 
Sridhara et al. 1995). It was advised not to use PSA level drops  as a surrogate marker for 
survival (Bubley et al. 1999).  
In patients with advanced disease, survival and quality of life, including pain palliation, are 
the most important criteria of clinical response. Besides survival these parameters are 
difficult to measure and subject to errors. With an attempt to standardize treatment 
response monitoring in cancer patients the European Organization for Research and 
Treatment of Cancer (EORTC) has developed quality of life questionnaires (EORTC QLQ-
C30 version 3.0). They were validated in many clinical trials (Aaronson et al. 1993). They 
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include questions on global health status / quality of life, functional scales and symptom 
scales. The functional scales are subdivided in physical functioning, role functioning, 
emotional functioning, cognitive functioning and social functioning. The symptom scales are 
subdivided in fatigue, nausea and vomiting, pain, dyspnoea, insomnia, appetite loss, 
constipation, diarrhoea and financial difficulties. Each domain was scored on a scale of 0 – 
100, according to the EORTC scoring manual (Fayers et al. 2001). The changes in scores may 
be used to monitor clinical effect. 
Other often used clinical monitoring tools include the visual analogue scales (VAS) to 
monitor pain, changes in analgesic intake and, more basic, the physician’s assessment based 
on anamnesis and physical examination. A matter of debate is the frequency of evaluation. It 
seems that daily assessment is necessary to appreciate the wide variation in clinical status 
that patients may experience from day to day (Han et al. 2002). In all cases it is difficult to 
find a good balance between accuracy and compliance. PSA is therefore still popular to 
measure an objective level of response (Bubley et al. 1999; Scher et al. 2008).  
However, other predictors of response may prove to be much more reliable than PSA. In 
hormone-refractory prostate cancer patients in advanced stages of their disease the extent of 
metastatic disease in the skeleton is of high prognostic significance (Sabbatini et al. 1999). 
Furthermore it was shown that patients with advanced disease who had experienced a so-
called Skeletal Related Event (defined as: pathologic fracture, spinal cord compression with 
vertebral compression fracture, the need for surgery to treat or prevent pathologic fractures or 
spinal cord compression, or the need for radiation to bone) had a significantly worse survival 
and poorer quality of life, in comparison with patients who had not experienced a Skeletal 
Related Event (DePuy et al. 2007). These results further confirm the importance to treat skeletal 
metastases adequately. Markers of skeletal metabolism were found to be related to outcome 
and survival. In several clinical studies in prostate cancer patients it was observed that 
markers of bone metabolism were able to predict outcome, both as absolute levels pre-
treatment and as changes after treatment (Jung et al. 2004; Lein et al. 2007). In large series of 
cancer patients, including a majority of prostate cancer patients, treated with zoledronic acid, it 
was found that baseline levels of the bone marker urinary N-terminal type I collagen peptide 
[NTX], as well as changes of NTX after treatment were able to predict improved survival 
(Coleman et al. 2005; Lipton et al. 2008). Other studies emphasized the importance of the bone 
marker serum bone specific alkaline phosphatase [BAP] as a predictor of outcome (Cook et al. 
2006; Smith et al. 2007). Most of these studies used the same bone markers as we did in the 
study on the combined treatment of prostate cancer patients with 153Sm-EDTMP and 
zoledronic acid (i.e. NTX, BAP and serum procollagen type I N propeptide [PINP],). Although 
this study comprised a small patient population the results are of interest because they confirm 
the utility of these markers as predictors of clinical outcome, even in small numbers (Lam et al. 
2007). Besides, they were first tested in the treatment monitoring of bone seeking 
radiopharmaceuticals. The bone formation markers BAP and PINP were in agreement with 
the clinical effect of the combined treatment regimen evaluated by EORTC questionnaires. The 
bone resorption marker NTX and PSA were not in agreement with the clinical effect. This 
supports the hypothesis that the extent of osteoblastic metastasis in hormone-refractory 
prostate cancer patients is an important parameter for clinical outcome. Both treatment itself 
and treatment monitoring should be directed to these osteoblastic metastases. Bone markers 
may well prove to be very useful predictors of clinical effect in the treatment with bone 
seeking radiopharmaceuticals. They should be used in future trials.  
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Last but not least the importance of imaging modalities should be mentioned with regard to 
individualized treatment monitoring. Functional rather than anatomical imaging techniques 
may be used to predict response. Several PET (Positron Emission Tomography) techniques 
are being developed for this purpose (John et al. 2008; Price et al. 2002). In fact, functional 
imaging will prove to be one of the major contributions of nuclear medicine to clinical 
oncology in the future. Does the treatment work? That question needs to be answered for 
each oncologic treatment on an individual basis. Nuclear imaging and PET in particular 
may be helpful. 
Besides predictors of efficacy, predictors of toxicity are equally important for individualized 
patient management. Radiopharmaceuticals are important resources in the management of 
bone pain, but they need to be utilized in a manner that does not prevent other systemic 
therapy (Rago 1998). Thrombocytopenia is the dose limiting factor in treatment of painful 
bone metastases with bone seeking radiopharmaceuticals. De Klerk et al evaluated  
thrombocytopenia in patients with hormone refractory prostate carcinoma, treated with 
186Re-HEDP (de Klerk et al. 1994). As an index of the extent of bone involvement, the bone 
scan index (BSI) was determined from the pre-treatment 99mTc-HDP scintigram. The BSI is a 
tool to describe the extent of skeletal metastases on a scale from 0 to 100% (Blake et al. 1986). 
They described a functional relation (r = 0.78; p < 0.001) of the percentage of platelet 
decrease after treatment with the extent and distribution of skeletal metastases (BSI) and 
administered activity, normalized to standard body surface area. Using this relation, it is 
possible to predict thrombocytopenia by pre-treatment skeletal scintigraphy and to adjust 
the dosage for each patient to avoid unacceptable toxicity (de Klerk et al. 1994). 
However, more sophisticated indices of bone marrow function might also be of 
paramount importance. Recently, some very interesting reports have been published on 
‘reticulated platelets’ (Briggs et al. 2004; Wang et al. 2002). In systemic radionuclide 
therapy, the megakaryocyte seems to be most vulnerable to radiation. It is of great interest 
to gain more knowledge of bone marrow function pre-treatment using ‘biological’ 
parameters like ‘reticulated platelets’. These newly released platelets are larger and 
contain RNA. They were suggested to be the platelet analogue of the red cell reticulocyt. 
Assessment of platelet production using ‘reticulated platelets’ would distinguish between 
thrombocytopenia due to bone marrow failure and impending bone marrow recovery 
after cytotoxic therapy or thrombocytopenia due to increased peripheral platelet 
destruction and turnover. In both cases platelet levels are low, but in the latter ‘reticulated 
platelet’ levels will be high due to increased production (Wang et al. 2002). This non-
invasive measurement could further increase our knowledge of platelet production and 
the influence of radiation on this process. 
By adding hematological, chemical and biological parameters, combined with the bone 
scan index, body surface area, administered activity and retained activity, an extended 
version of ‘De Klerk’s formula’ may be developed. This is probably best done as a so 
called nomogram. Smaletz et al developed a nomogram to predict survival for patients 
with hormone refractory prostate carcinoma (Smaletz et al. 2002). A nomogram is a model 
in which individual parameters lead to a chance (from 0 to 100%) to experience a pre-
defined outcome. The outcome may be defined as survival or for example toxicity. Such a 
model can be made to predict hematological toxicity (thrombocytopenia, leucopenia) after 
treatment with bone seeking radiopharmaceuticals to improve individualized patient 
management. 
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6. Future prospects 
Several future implications have already been discussed above. One of the most important 
developments for bone seeking radiopharmaceuticals will be individualized medicine. The 
search for an optimized balance between efficacy and toxicity will be found rather in an 
individualized treatment plan than in new agents. Good predictors of efficacy and toxicity 
are needed for treatment monitoring. Several potential candidates were described above. 
They may be found in clinical evaluation, imaging and several laboratory parameters. A 
combination of these parameters may lead to a prediction model which may be used in 
daily practice. 
Multimodality treatment has also been described above. Many combinations have 
potential. It has to be investigated which regimen will be most effective. Besides a direct 
anti-tumor effect which may be reached with chemotherapy (i.e. docetaxel), it is 
recognized that treatment directed to the bony environment may add to the overall 
efficacy of the treatment regimen. Bone seeking radiopharmaceuticals are bone-directed 
and may be of value in combination with other treatment modalities. Besides 
combinations with chemotherapy or bisphosphonates other interesting combinations may 
include for example atrasentan, or denosumab. 
An important other issue is the timing of treatment with bone seeking radiopharmaceuticals. 
The frequency and interval of sequential treatment should be considered. Bone seeking 
radiopharmaceuticals are mostly used as a single shot treatment. When patients respond to the 
treatment repeated treatment is considered. In most instances this does not happen with a 
planned interval in mind but rather when symptoms reappear after an initial response. In fact 
this might be too late. It seems better to treat patients sequentially before symptoms reoccur. 
This was confirmed in a randomized controlled trial in prostate cancer patients treated with 
two dosages of 1.1 mCi 188Re-HEDP with an interval of eight weeks compared to single shot 
treatment. They did not only find an improved pain response with longer duration but 
surprisingly an improved survival as well (Palmedo et al. 2003). Safety of repeated treatment 
with bone seeking radiopharmaceuticals was also confirmed (Sartor et al. 2007). This 
enhancement of efficacy may be attributed to chronic inhibition of osseous metabolism 
preventing cancer cells to thrive in the bony environment. Most other oncologic compounds 
are used in a repeated fashion using several cycles to reach sufficient effect.  It should be 
investigated which multiple treatment regimen is most suitable for bone seeking 
radiopharmaceuticals, and whether it is safe and more effective. It may be suggested that 
the best result in hormone-refractory will be reached using a multimodality treatment 
regimen with fractionation of all treatments to be effective over a prolonged period of time.  
7. Conclusion 
Treatment with bone seeking radiopharmaceuticals in patients with multiple painful 
skeletal metastases is safe and effective when proper protocols are being used. Important 
improvements may be found in multimodality treatment in long-term treatment regimens 
and in individualized patient management. Identification of powerful indicators of 
toxicity and efficacy may guide patient selection and therapy monitoring to optimize the 
patient’s outcome. This may possibly lead us beyond pain palliation towards 
improvement of survival. 
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